Act of omission

Public institutions do not seek permission from the biodiversity authority before genetically manipulating crops

Cipla's audacious move

Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug

US keeps India out of Priority Foreign Country list of 'worst IP offenders'

US Trade Representative’s Special 301 Report keeps up pressure on India to fall in line with US’ interests

The natco-pfizer test

Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India

It’s still open season for bio-piracy

Rich nations block accord on benefit-sharing rules for the world’s genetic resources

Gunning for green tech

US continues to target India over its intellectual property regime, especially in pharma, green tech sectors

What's with this Kolaveri about John Doe injunctions?

In jurisdictions where the law of copyright is much more matured as compared to India, the injunctions are issued very judiciously, and by …

Gopal Subramaniam, Rohinton Nariman swap places in Novartis patent case

 Will take on each other in the patent case of anti-cancer drug Glivec filed by Novartis

Choking access to drugs

Drug prices are likely to increase as rich countries and their pharma companies squeeze Indian generics out of the market. How can India’s …

Patent hypocrisies of US

American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards

Any cheers for Doha pact?

The Doha Declaration on protecting public health is a decade old, but developing countries have not been able to make use of TRIPs flexibilities

No climate for cleantech

Most of the clean energy innovations are with just six rich countries and hardly any technology is coming to developing nations

A lethal secrecy in trade deals

Why do democratic governments hide trade negotiations that have dire consequences for public services?

Pursuing a nationalist IPR policy

India has enough laws to protect its intellectual property rights. It is the implementation that is wanting

The pirates come ashore

German Pirate Party’s strong showing in the May elections is a sign that anti-IPR movements resonate with the people

Patent issues delaying Ebola cure

Canada's exclusive licensing rights of its Ebola patent to a US firm are holding up global development of a vaccine

ACTA fury goes viral

Europe is on the boil over an anti-piracy bill that will curb Internet freedom but its impact on trade in generic medicines is not on the radar

Global report on challenges faced by seed sector launched

Focuses on need to stop seed laws that are preventing farmers from saving and exchanging their indigenous varieties  

What Durban did not discuss

IPRs are blocking access to mitigation and adaptation technologies. India offers a way out

New endosulfan ploy

Industry is sidestepping issues by pitching the proposed UN ban on endosulfan as the battle between generics and patented pesticides

Predatory EU pacts

EU is pushing India and Canada to sign free trade agreements that will hurt their generic drugs—and the outrage is global

WTO gives India a clean chit

Apex trade regulator finds nothing amiss in India's intellectual property laws after exhaustive review

Taken by the horns

Gujarat buckles under farmers’ pressure, shrinks special investment region planned for industries

A people’s festival to protest CBD conference

Non-profits to represent united resolve to protect the country’s natural wealth and bio-cultural heritage from powerful economic interests

Environment ministry rapped

Parliament committee says serious inadequacies in afforestation, biodiversity programmes